New online first articles from JAMA Dermatology (2024)

Erenumab for Treatment of Persistent Erythema and Flushing in Rosacea: A Nonrandomized Controlled Trial

Nita K. F.Wienholtz,MD, PhD; Casper E.Christensen,MD, PhD; Thien P.Do,MD, PhD; et al.

JAMA Dermatol. Published online April 17, 2024. doi:10.1001/jamadermatol.2024.0408

This nonrandomized controlled trial analyzes the efficacy and safety of erenumab, an anti–calcitonin gene-related peptide receptor monoclonal antibody, for rosacea-associated erythema and flushing.

• Editor's Note

  Potential Role of Calcitonin Gene-Related Peptide Inhibitors in the Treatment of Rosacea Flushing and Erythema

  John S.Barbieri,MD, MBA

  JAMA Dermatol

Weekly Pulsed Dye Laser Treatments for Port-Wine Birthmarks in Infants

ShirinBajaj,MD; JoyTao,MD; David A.Hashemi,MD, MBA; et al.

JAMA Dermatol. Published online April 17, 2024. doi:10.1001/jamadermatol.2024.0293

This case series examines the improvement in port-wine birthmark clearance from before to after once-weekly pulsed dye laser therapy in patients younger than 6 months.

Potential Role of Calcitonin Gene-Related Peptide Inhibitors in the Treatment of Rosacea Flushing and Erythema

John S.Barbieri,MD, MBA

JAMA Dermatol. Published online April 17, 2024. doi:10.1001/jamadermatol.2024.0397

Laser and Light-Based Therapies for Hirsutism Management in Women With Polycystic Ovarian Syndrome: A Systematic Review

KatrinaTan,MD; ThisaraCoster,MBiomedHlthSc; AyaMousa,PhD; et al.

has active quiz

JAMA Dermatol. Published online April 17, 2024. doi:10.1001/jamadermatol.2024.0623

This Systematic Review synthesizes the existing literature regarding the effectiveness of laser and light hair reduction therapies, either as stand-alone treatments or in combination with systemic agents, in treating hirsutism for women with polycystic ovary syndrome.

Chronic Progressive Pink-Yellow Papules and Nodules in a Middle-Aged Man

Jessica A.Kern,BS; Brian R.Hinds,MD; VeronicaShi,MD

has active quiz

JAMA Dermatol. Published online April 17, 2024. doi:10.1001/jamadermatol.2024.0227

A 38-year-old man presented with numerous pink-yellow firm papules and nodules on the bilateral elbows for 10 years spreading to the hands and knees in the past year. What is your diagnosis?

Hospitalization and Continuity of Care in Anti-MDA5 Dermatomyositis

William MarkRichardson,MD; Jill T.Shah,BA; Daniel R.Mazori,MD; et al.

JAMA Dermatol. Published online April 17, 2024. doi:10.1001/jamadermatol.2024.0403

This cohort study describes the clinical features, patient characteristics, and treatment of anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis.

Treatment of Keratosis Lichenoides Chronica With Upadacitinib

JingyiTang,MD, PhD; FangLiu,MD, PhD; WenjunLiao,MD, PhD; et al.

JAMA Dermatol. Published online April 17, 2024. doi:10.1001/jamadermatol.2024.0755

This case report describes a 30-year-old man presenting with 1-year history of nonitchy red papules and patches who was subsequently treated with upadacitinib.

Error in Table

free access

JAMA Dermatol. Published online April 17, 2024. doi:10.1001/jamadermatol.2024.1011

Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial

Mariana AlvaresPenha,MD, MSc; Hélio AmanteMiot,MD, PhD; MichalKasprzak,PhD; et al.

JAMA Dermatol. Published online April 10, 2024. doi:10.1001/jamadermatol.2024.0284

This randomized clinical trial compares the efficacy, safety, and tolerability of daily oral minoxidil, 5 mg, with twice-daily topical minoxidil, 5%, for 24 weeks in the treatment of male androgenetic alopecia.

Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial

Rose C.Velasco,MA, MD; ConnieShao,BA; BrettCutler,MD; et al.

JAMA Dermatol. Published online April 10, 2024. doi:10.1001/jamadermatol.2024.0257

This nonrandomized trial examines outcomes with treatment with guselkumab for patients with pityriasis rubra pilaris.

Chronic Mucocutaneous Candidiasis Due to STAT1 Gene Variant

DanruiJing,MD; GuanzhaoLiang,MD, PhD; XiaofangLi,MD, PhD

has active quiz

JAMA Dermatol. Published online April 10, 2024. doi:10.1001/jamadermatol.2024.0617

This case report describes a man in his 40s who presented with a 5-month history of recurrent pruritic papular erythema with mild scaling on the face, left forearm, and groin.

Onychomycosis

Adam I.Rubin,MD

free access

JAMA Dermatol. Published online April 10, 2024. doi:10.1001/jamadermatol.2023.5194

This Patient Page describes the risk factors, clinical features, diagnosis, and treatment of onychomycosis.

Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use

PushkarAggarwal,MD, MBA; DeniseClark,MD, MS; AatmanShah,MD; et al.

JAMA Dermatol. Published online April 10, 2024. doi:10.1001/jamadermatol.2024.0390

This cross-sectional study assesses risk of dermatological immune-related adverse events associated with immunotherapy for cancer.

Assessing Time of Onset for Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Dermatomyositis

Rachel R.Lin,BS; Peyton V.Warp,BS; Andrea D.Maderal,MD; et al.

JAMA Dermatol. Published online April 10, 2024. doi:10.1001/jamadermatol.2024.0507

This cohort study seeks to describe the time interval between interstitial lung disease and anti–melanoma differentiation-associated gene 5 antibody-positive dermatomyositis diagnoses.

Emergency Contraception for Patients Taking Isotretinoin

SarahGold,BA; SarahHorvath,MD; AndreaZaenglein,MD

JAMA Dermatol. Published online April 3, 2024. doi:10.1001/jamadermatol.2024.0189

This Viewpoint explains the need for emergency contraception as the last chance to avoid pregnancy for patients taking isotretinoin.

Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole–Induced Severe Cutaneous Adverse Reactions: A Systematic Review and Meta-Analysis

Po-ChienWu,MD; Wei-TiChen,MD, MS; I-HsinHuang,MD; et al.

JAMA Dermatol. Published online April 3, 2024. doi:10.1001/jamadermatol.2024.0210

This systematic review and meta-analysis examines the association between human leukocyte antigen genotypes and sulfamethoxazole/cotrimoxazole–induced severe cutaneous adverse reactions.

• Editor's Note

  Precision in Language Regarding Geographic Region of Origin in Severe Cutaneous Adverse Drug Reaction Research

  Mya L.Roberson,PhD

  JAMA Dermatol

Barriers and Facilitators Affecting Long-Term Antibiotic Prescriptions for Acne Treatment

Ronnie A.Festok,BA; Avni S.Ahuja,BA; Jared Y.Chen; et al.

JAMA Dermatol. Published online April 3, 2024. doi:10.1001/jamadermatol.2024.0203

This qualitative study assesses antibiotic prescribing practices for acne to identify challenges to antibiotic stewardship among dermatologists.

Precision in Language Regarding Geographic Region of Origin in Severe Cutaneous Adverse Drug Reaction Research

Mya L.Roberson,PhD

JAMA Dermatol. Published online April 3, 2024. doi:10.1001/jamadermatol.2024.0202

Cutaneous Stigmata of Bacterial Endocarditis

MatteoCastrichini,MD; Robert J.Haemmerle,MD; Pritish K.Tosh,MD

has active quiz

JAMA Dermatol. Published online April 3, 2024. doi:10.1001/jamadermatol.2024.0481

This case report describes Osler nodes and Janeway lesions on a man in his 70s.

Red Nodule on the Scalp in a Healthy Young Man

Constanzadel Puerto,MD; SoledadAspillaga,MD; AlexCastro,MD

has active quiz

JAMA Dermatol. Published online April 3, 2024. doi:10.1001/jamadermatol.2024.0146

A man in his 40s was referred for an 8-mm red, firm, mobile nodule with irregular red lacunae and vessels and an absence of septa. What is your diagnosis?

Tofacitinib Treatment for Pretibial Myxedema

SuWang,MD; XinyiChen,MD; JuanBai,MD; et al.

JAMA Dermatol. Published online April 3, 2024. doi:10.1001/jamadermatol.2024.0344

This case report describes tofacitinib treatment for 2 patients with pretibial myxedema.